

Via Facsimile and U.S. Mail
Mail Stop 4720

May 27, 2010

Mr. David P. Holveck
President and Chief Executive Officer
100 Endo Pharmaceuticals Holdings, Inc.
Chadds Ford, PA 19317

**Re: Endo Pharmaceuticals Holdings, Inc.
Form 10-K Filed March 1, 2010
Definitive Proxy Statement Filed April 29, 2010
File No. 001-15989**

Dear Mr. Holveck:

We have reviewed your May 3, 2010 response to our April 19, 2010 comment letter and have the following additional comments. In our comments, we ask you to provide us with information to better understand your disclosure. Where it requests you to revise disclosure, the information you provide should show us what the revised disclosure will look like and identify the annual or quarterly filing, as applicable, in which you intend to first include it. If you do not believe that revised disclosure is necessary, explain the reason in your response. After reviewing the information provided, we may raise additional comments and/or request that you amend your filing.

Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or on any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter.

Form 10-K for the year ended December 31, 2010

Service Agreements, page 21

1. We note your response to comment 3. Please also disclose how much you would be required to pay, or an estimate of what you would be required to pay, if you terminate the agreement with UPS. Also, clarify if you would be required to make these payments if UPS terminates the agreement.

Acquisitions, License and Collaboration Agreements, page 21

2. We note your response to comment 5. The confidential treatment request relating to the Teva agreement was granted pursuant to a procedure by which we did not perform a full review of your request and we retained the right to revisit the issue. Additionally, we have requested disclosure of the range within which the royalty rate falls. Therefore, our comment is reissued. Please expand the discussion of the Teva agreement to disclose the royalty rate range for payments Teva will be required to pay pursuant to the agreement and the royalty rate range you will be required to pay Teva if you terminate the agreement. Please note you are required to indicate the exhibits that are subject to confidential treatment in the exhibit index.

Definitive Proxy Statement filed April 29, 2010

Compensation Discussion and Analysis, page 27

3. We note that you have not included any disclosure in response to Item 402(s) of Regulation S-K. Please advise us of the basis for your conclusion that disclosure is not necessary and describe the process you undertook to reach that conclusion.
4. Please include the disclosure required by Item 407(c)(2)(vi) of Regulation S-K regarding whether, and if so how, the Nominating & Governance Committee considers diversity in identifying nominees for director.

Fiscal Year 2009 Decisions Regarding Incentive Compensation, page 33

5. We note your statement that the annual performance goals reflect the confidential operating plan and information. We disagree that revenue and earnings per share targets are confidential information. Please provide the specific targets and discuss the extent to which the corporate and individual goals were achieved. To the extent you believe the other goals are confidential and disclosure would cause competitive harm, please present an analysis supporting your belief. Your analysis should identify the goals and explain how disclosure is likely to cause competitive harm. You can request confidential treatment for portions of your analysis pursuant to Rule 83. Alternatively, provide a more specific description

Mr. Holveck
Endo Pharmaceuticals Holdings, Inc.
May 27, 2010
Page 3

of your other corporate and individual goals and discuss the extent of achievement of each goal. To the extent the goals were quantified, your discussion should also be quantified, including thresholds, targets and maximums, as applicable.

6. We note your disclosure that 40% of the cash incentive compensation was based on financial goals, 30% was based on portfolio development and 30% was based on organizational advancement objectives. Please explain how the committee considered individual objectives in determining cash incentive compensation.

Fiscal Year 2009 Decisions Regarding Long-Term Equity-Based Incentive Program, page 36

7. On page 36 you have stated that the award percentages reflected the committee's judgment as to the extent to which the individual named executive officers impacted the company's performance and the achievement of the company's 2009 goals and objectives. Please expand your disclosure to describe the factors the committee considered in determining each executive officer's award percentage.

Please provide us the information requested within 10 business days or tell us when you will provide us with a response. Please furnish a cover letter with your response that keys your responses to our comments and provide any requested information. Detailed cover letters greatly facilitate our review. Please furnish your letter on EDGAR under the form type label CORRESP.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes all information required under the Securities Exchange Act of 1934 and that they have provided all information investors require for an informed investment decision. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made. In connection with responding to our comments, please provide, in your letter, a statement from the company acknowledging that:

- the company is responsible for the adequacy and accuracy of the disclosure in the filing;
- staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
- the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Mr. Holveck
Endo Pharmaceuticals Holdings, Inc.
May 27, 2010
Page 4

In addition, please be advised that the Division of Enforcement has access to all information you provide to the staff of the Division of Corporation Finance in our review of your filing or in response to our comments on your filing.

Please contact Michael Rosenthal, Staff Attorney, at (202) 551-3674, Suzanne Hayes, Legal Branch Chief at (202) 551-1675 or me at (202) 551-3715 if you have any questions regarding the processing of your response as well as any questions regarding comments and related matters.

Sincerely,

Jeffrey Riedler
Assistant Director